Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 23:11:695647.
doi: 10.3389/fonc.2021.695647. eCollection 2021.

Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review

Stine Elleberg Petersen  1 , Morten Høyer  1
Affiliations
Review

Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review

Stine Elleberg Petersen et al. Front Oncol. .

Abstract

Purpose: There is high-level evidence for addition of androgen deprivation therapy to photon-based radiotherapy of the prostate in intermediate- and high-risk prostate cancer. Little is known about the value of ADT in particle therapy of prostate cancer. We are conducting a systematic review on biochemical disease-free survival, overall survival, and morbidity after combined particle therapy and ADT for prostate cancer.

Methods: A thorough search in PubMed, Embase, Scopus, and Web of Science databases were conducted, searching for relevant studies. Clinical studies on prostate cancer and the treatment combination of particle therapy and androgen deprivation therapy were included. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered on PROSPERO (CRD42021230801).

Results: A total of 298 papers were identified. Fifteen papers reporting on 7,202 patients after proton or carbon-ion therapy for localized prostate cancer where a fraction or all patients received ADT were selected for analysis. Three thousand five hundred and nineteen (49%) of the patients had received combined ADT and particle therapy. Primarily high-risk (87%), to a lesser extent intermediate-risk (34%) and low-risk patients (12%) received ADT. There were no comparative studies on the effect of ADT in patients treated with particles and no studies identified ADT as an independent prognostic factor related to survival outcomes.

Conclusions: The review found no evidence to support that the effects on biochemical disease-free survival and morbidity of combining ADT to particle therapy differs from the ADT effects in conventional photon based radiotherapy. The available data on the topic is limited.

Keywords: acute morbidity; androgen deprivation therapy; biochemical disease-free survival; carbon ion therapy; late morbidity; overall survival; prostate cancer; proton therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of inclusion and exclusion procedure.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. 10.3322/caac.21492 - DOI - PubMed
    1. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. . Endocrine Treatment, With or Without Radiotherapy, in Locally Advanced Prostate Cancer (SPCG-7/SFUO-3): An Open Randomised Phase III Trial. Lancet (2009) 373(9660):301–8. 10.1016/s0140-6736(08)61815-2 - DOI - PubMed
    1. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. . External Irradiation With or Without Long-Term Androgen Suppression for Prostate Cancer With High Metastatic Risk: 10-Year Results of an EORTC Randomised Study. Lancet Oncol (2010) 11(11):1066–73. 10.1016/s1470-2045(10)70223-0 - DOI - PubMed
    1. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. . Duration of Androgen Suppression in the Treatment of Prostate Cancer. N Engl J Med (2009) 360(24):2516–27. 10.1056/NEJMoa0810095 - DOI - PubMed
    1. Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, et al. . Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol (2016) 34(15):1748–56. 10.1200/jco.2015.64.8055 - DOI - PubMed

LinkOut - more resources